102
Participants
Start Date
August 31, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Insulin Glargine
Glargine-injectable, variable, once daily (QD), 6 months
Metformin
Metformin-oral, up to 1000mg, twice daily (BID), 6 months
Prandial insulin
Aspart or glulisine or lispro
Exenatide
Injectable, 5mcg, twice daily (BID), 6 months
Kaledia Health of Western New York, Buffalo
Diabetes Care Center, Durham
Atlanta Diabetes Associates, Atlanta
University of Miami, Miami
International Diabetes Center, Minneapolis
Washington University, St Louis
So Calif. Permanente Medical Group, San Diego
Oregon Health and Science University, Portland
University of Washington, Seattle
Washington State University Spokane, College of Pharmacy Spokane WA 99202 USA, Spokane
Joslin Diabetes Center, Boston
University of Vermont, Colchester
Eli Lilly and Company
INDUSTRY
Sanofi
INDUSTRY
Astra Zeneca, Bristol-Myers Squibb
OTHER
DexCom, Inc.
INDUSTRY
Bayer
INDUSTRY
Becton, Dickinson and Company
INDUSTRY
Medicomp
UNKNOWN
University of Texas
OTHER
US Department of Veterans Affairs
FED
Biomedical Research Institute of New Mexico
OTHER
University of Washington
OTHER